Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExPEC4V in Healthy Japanese Adults
NCT02748967Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2016
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ExPEC4V in extraintestinal pathogenic Escherichia coli infection, sponsored by Janssen Pharmaceutical. Started Apr 2016; status: completed.
02
Drugs
ExPEC4V
03
Conditions
extraintestinal pathogenic Escherichia coli infection
Beyond the preview
Go deeper on NCT02748967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02748967.